Mesoblast’s (MESO) Buy Rating Reaffirmed at Maxim Group

Maxim Group reaffirmed their buy rating on shares of Mesoblast (NASDAQ:MESO) in a report released on Thursday, AnalystRatings.com reports. The brokerage currently has a $16.00 price target on the stock.

A number of other analysts have also weighed in on MESO. Oppenheimer set a $10.00 price objective on shares of Mesoblast and gave the stock a buy rating in a research report on Tuesday. Zacks Investment Research lowered shares of Mesoblast from a buy rating to a hold rating in a research report on Friday, September 6th. HC Wainwright set a $7.00 price objective on shares of Mesoblast and gave the stock a buy rating in a research report on Friday, August 30th. Chardan Capital set a $6.00 price objective on shares of Mesoblast and gave the stock a hold rating in a research report on Friday, August 30th. Finally, ValuEngine raised shares of Mesoblast from a hold rating to a buy rating in a research report on Tuesday. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Mesoblast has a consensus rating of Buy and an average target price of $11.25.

Mesoblast stock traded up $0.48 during midday trading on Thursday, reaching $7.23. The stock had a trading volume of 111,771 shares, compared to its average volume of 49,189. The company has a quick ratio of 1.92, a current ratio of 1.41 and a debt-to-equity ratio of 0.14. Mesoblast has a 52-week low of $3.35 and a 52-week high of $8.78. The firm has a market cap of $572.56 million, a price-to-earnings ratio of -7.95 and a beta of 1.77. The company has a fifty day moving average of $5.06 and a 200 day moving average of $5.09.



Mesoblast (NASDAQ:MESO) last posted its quarterly earnings data on Thursday, August 29th. The company reported ($0.21) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.02. Mesoblast had a negative net margin of 536.97% and a negative return on equity of 17.66%. The company had revenue of $1.97 million for the quarter, compared to analyst estimates of $1.31 million. Equities research analysts predict that Mesoblast will post -0.86 EPS for the current year.

An institutional investor recently raised its position in Mesoblast stock. Morgan Stanley grew its stake in Mesoblast limited (NASDAQ:MESO) by 284.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 147,702 shares of the company’s stock after acquiring an additional 109,295 shares during the period. Morgan Stanley owned 0.16% of Mesoblast worth $784,000 at the end of the most recent reporting period. 2.76% of the stock is currently owned by institutional investors.

Mesoblast Company Profile

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.

See Also: What is a back-end load?

Analyst Recommendations for Mesoblast (NASDAQ:MESO)

Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.